Rozanolixizumab (UCB7665)
| Disease area studied | Abbreviated title | Phase | Study ID | Registry database | Study results | Plain language summary | Publication (if available) |
|---|---|---|---|---|---|---|---|
| Myasthenia Gravis | A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis | Phase 2 |
MG0002
Completed |
NCT03052751 2016-002698-36 |
LINK LINK |
Bril V. Neurology 2021, 96(6):e853-e865 | |
| Myasthenia Gravis | A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis | Phase 3 |
MG0003
Completed |
NCT03971422 2019-000968-18 |
LINK
|
Bril V.; Muscle & nerve 2022; 65(S1):S35, MGFA 2022; Miami, Florida, USA Habib, A.A. Muscle & nerve 2022; 65(S1):S19-S20, MGFA 2022 | |
| Autoimmune Encephalitis | A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis | Phase 2 |
AIE001
Ongoing |
NCT04875975 2019-004778-25 |
Dubey D., Titulaer M., Koul A.D., Yates S., Irani S.R. , Neurology 2022; 99(23 suppl.2):S42-S43, AAN 2022 | ||
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy | A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 2 |
CIDP01
Completed |
NCT03861481 2016-002411-17 |
LINK LINK |
Querol L., de Seze J., Dysgaard T., Levine T., Rao T.H. et al. , J Periph Nerv Syst 2022; 27(S3 suppl.):S110-111, 2022 Peripheral Nerve Society Annual Meeting, May 14-17, 2022; Miami, Fl, USA | |
| Thrombocytopenia | Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia | Phase 2 |
TP0001
Completed |
NCT02718716 2015-003984-12 |
LINK
|
Robak T., Blood advances 2020; 4(17):4136–46 | |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy | A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 2 |
CIDP04
Completed |
NCT04051944 2018-004392-12 |
LINK [LINK |
||
| Myasthenia Gravis | A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis | Phase 3 |
MG0004
Completed |
NCT04124965 2019-000969-21 |
LINK
|
||
| Myasthenia Gravis | A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis | Phase 3 |
MG0007
Ongoing |
NCT04650854 2020-003230-20 |
|||
| Myelin oligodendrocyte glycoprotein antibody-associated disease | A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD) (cosMOG) | Phase 3 |
MOG001
Ongoing |
NCT05063162 2021-000352-19 |
|||
| Primary Immune Thrombocytopenia | The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and asses safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia (ITP). | Phase 3 |
TP0003
Terminated |
NCT04200456 2019-000884-26 |
|||
| Primary Immune Thrombocytopenia | A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) | Phase 3 |
TP0004
Completed |
NCT04596995 2019-000883-40 |
|||
| Fibromyalgia | A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome | Phase 2 |
FM0001
Ongoing |
NCT05643794 | |||
| Persistent or Chronic Primary Immune Thrombocytopenia (ITP) | A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy2) | Phase 3 |
TP0006
Terminated |
NCT04224688 2019-003451-11 |